Most stocks can be classified into either the growth or value category. But, can a growth stock also be a value stock? If these three stocks are any indication, the answer is a resounding "Yes!"
The biotech sector has already had an incredible run, but these two stocks look as if their momentum could continue for years to come.
Nearly 90% of biotech stocks are losing money, but that doesn't mean our healthcare analysts don't perceive there to be value in the sector.
Biotech stocks have been dramatically outperforming the broader market, but that doesn't mean they're free of risk. Here are three types of risks all biotech stocks face.
Biotech stocks have nearly doubled the return of the S&P 500 since March 2009. Can the run higher continue, or have valuations among biotech stocks entered bubble territory?
One report claims Internet of Things devices will grow from nearly 4.9 billion units installed in 2015 to 25 billion by 2020. Yet, in spite of this rapid growth potential, these three stocks could leave the Internet of Things in the dust.
Just because these stocks are near their highs doesn't mean you should hang on to them.
When it comes to the most profitable businesses in biotech, these 10 companies are the cream of the crop.
Mega-cap stocks are generally profitable and overflowing with free cash, leading many to pay handsome dividends. However, these three mega-cap stocks aren't currently paying a dividend -- and if their management teams are smart, they'll keep it that way for many years to come!
The hot burrito roller's stock cools down, and it was the right move.